The improved killing of both androgen-dependent and independent prostate cancer cells by etoposide loaded SPIONs coupled with NIR irradiation

Onbasli, Kubra; Erkısa, Merve; Demirci, Gozde; Muti, Abdullah; Ulukaya, Engin; Sennaroğlu, Alphan; Acar, Havva Yağcı

doi:10.1039/d2bm00107a

Cited by 11 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nanoparticles were prepared, as shown in Figure 1. First, anionic PAA coated SPIONs were synthesized by a co‐precipitation method as described previously by our group [39] . Then, Cet was conjugated to SPIONs to target EGFR overexpressing cells via a 2 kDa PEG spacer to enhance the availability of Cet to EGFRs.…”

Section: Resultsmentioning

confidence: 99%

“…First, anionic PAA coated SPIONs were synthesized by a co-precipitation method as described previously by our group. [39] Then, Cet was conjugated to SPIONs to target EGFR overexpressing cells via a 2 kDa PEG spacer to enhance the availability of Cet to EGFRs. Briefly, NH 2 -PEG-MI was conjugated to PAA@SPIONs using EDC/ NHS chemistry.…”

Section: Preparation and Characterization Of Cet-conjugated Bod-se-i ...mentioning

confidence: 99%

See 1 more Smart Citation

Superior Photodynamic Therapy of Colon Cancer Cells by Selenophene‐BODIPY‐Loaded Superparamagnetic Iron Oxide Nanoparticles

et al. 2022

View full text Add to dashboard Cite

Development of targeted nanoparticles as carriers to deliver photosensitizers to cancer cells is highly beneficial for ensuring the expected therapeutic outcome of photodynamic therapy. Herein, polyacrylic acid (PAA) coated superparamagnetic iron oxide nanoparticles (SPIONs), conjugated with endothelial growth factor receptor (EGFR) targeting Cetuximab (Cet) were loaded with a BODIPY-based (BOD-Se-I) photosensitizer (Cet-PAA@SPION/BOD-Se-I) to achieve enhanced and selective photodynamic therapy on colon cancer cells. In vitro studies showed that Cet-PAA@SPION/BOD-Se-I improved phototoxicity dramatically compared to free BOD-Se-I on the HT29 cell line due to high uptake of the photosensitizer via endothelial growth factor receptor. Most importantly, the developed nanoagent completely eliminated the phototoxicity of BOD-Se-I on the healthy L929 cell line.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Preparation and Characterization Of Cet-conjugated Bod-se-i ...mentioning

confidence: 99%

Superior Photodynamic Therapy of Colon Cancer Cells by Selenophene‐BODIPY‐Loaded Superparamagnetic Iron Oxide Nanoparticles

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, in preclinical studies they were object of intense studies to engineering their surface with targeting molecules [ 52 ] to increase their residence time and internalization in cancer cells. These manipulations focused also on conjugating therapeutic agents on their surface comprising both small molecules [ 53 ] and biologics [ 50 ]. Attempts at exploiting polarized magnetic fields to increase their tumor targeting were proposed as well [ 54 ].…”

Section: Inorganic Npsmentioning

confidence: 99%

Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine

Parodi

Kolesova

Voronina

et al. 2022

IJMS

View full text Add to dashboard Cite

The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concept of treatments based on physical treatments and biologics. In this review, we considered different platforms that reached the clinical trial investigation, providing an objective analysis about their physical and chemical properties and the working mechanism at the basis of their tumoritr opic properties. With this review, we aim to help other scientists in the field in conceiving their delivering platforms for clinical translation by providing solid examples of technologies that eventually were tested and sometimes approved for human therapy.

show abstract

“…15 Our group studied chemo/photothermal therapy (PTT) combination on androgendependent and independent PCa cells using superparamagnetic iron oxide nanoparticles as a drug delivery vehicle and PTT agent. 16 Cells treated with 2MPA-NPLs between 5-100 mg Cd mL À1 concentration showed no loss in viability, suggesting these NPLs are non-toxic in the studied range (Fig. S3, ESI †).…”

mentioning

confidence: 93%

“…15 Our group studied chemo/photothermal therapy (PTT) combination on androgen-dependent and independent PCa cells using superparamagnetic iron oxide nanoparticles as a drug delivery vehicle and PTT agent. 16…”

mentioning

confidence: 99%

Aqueous colloidal nanoplatelets for imaging and improved ALA-based photodynamic therapy of prostate cancer cells

Onbasli¹,

Demirci²,

Işık³

et al. 2023

Chem. Commun.

Self Cite

View full text Add to dashboard Cite

show abstract

The improved killing of both androgen-dependent and independent prostate cancer cells by etoposide loaded SPIONs coupled with NIR irradiation

Abstract: Etoposide (Eto) is a toxic drug showing promise in treating prostate cancer (PCa), but suffers from significant side effects, poor solubility and bioavailability. Nanoparticles are quite successful in solving such...

Cited by 11 publications

References 34 publications

Superior Photodynamic Therapy of Colon Cancer Cells by Selenophene‐BODIPY‐Loaded Superparamagnetic Iron Oxide Nanoparticles

Superior Photodynamic Therapy of Colon Cancer Cells by Selenophene‐BODIPY‐Loaded Superparamagnetic Iron Oxide Nanoparticles

Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine

Aqueous colloidal nanoplatelets for imaging and improved ALA-based photodynamic therapy of prostate cancer cells

Contact Info

Product

Resources

About